Pleiotropic Anti-inflammatory Mechanisms of Statins: Crosstalk between Lipid Metabolism, Immune Modulation, and Cellular Signaling Pathways

Subject Areas : Journal of Chemical Health Risks

Peyman Bakhshaei Shahrebabaki ¹ , Raed Fanoukh Aboqader ² , Alizamen Salehifard Jouneghani ³ , Mukhayya Djumaniyazova Middle Khusinovna ⁴ , Alireza Salehifard Jouneghani ⁵ , Yuldoshev Jushkinbek Erkaboy ugli ⁶ , Umida Sadikova ⁷ , Norbek Kholboyev ⁸ , Farnaz Farzaneh Dehkordi ^{9 *} , Farhad Safarpoor Dehkordi ¹⁰

1 - Department of Vascular and Endovascular Surgery, Ayatollah taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran , Iran.
2 - Al-Aouadi College of Medicine, Al-Ayen Iraqi University, AUIQ, An Nasiriyah, Iraq.
3 - Department of Pediatrics, College of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
4 - Pedagogy and Psychology Department, Pedagogy Faculty, Urganch State University.
5 - Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
6 - Intern teacher of the "Pedagogy and Primary Education Methodology" department of Urgench Innovation University
7 - Department of Psychology and Medicine. Mamun university, Khiva, Uzbekistan
8 - Department of Medicine, Termez University of Economics and Service, Termez, Uzbekistan. [e-mail]
9 - Department of biology , Ard.c., Islamic Azad university, Ardebil, Iran
10 - Department of Food Hygiene, University of Tehran, Tehran, Iran.

Received: 2025-05-27 Accepted : 2025-08-17 Published : 2025-06-15

Keywords: Statins, lipid metabolism, inflammatory diseases, autoimmune, cancer,

Abstract :

Statins, primarily known for their lipid-lowering properties, have emerged as significant agents in the field of anti-inflammatory and immunomodulatory therapies. This paper explores the pleiotropic effects of statins, which extend beyond cholesterol reduction, contributing to cardiovascular protection and potential therapeutic applications in various inflammatory and autoimmune diseases. The mechanisms by which statins exert these effects include the inhibition of isoprenoid-dependent signaling pathways, modulation of cytokine production, enhancement of endothelial function, and attenuation of immune cell activation. These actions are particularly relevant in conditions characterized by chronic inflammation, such as multiple sclerosis (MS) and neurodegenerative disorders. Research indicates that statins may mitigate the progression of MS, a disease marked by inflammation and myelin damage in the central nervous system, potentially offering protective benefits through their anti-inflammatory properties. Furthermore, studies have shown that statins can cross the blood-brain barrier, making them candidates for reducing neuroinflammation and delaying cognitive decline in diseases like Alzheimer's and Parkinson's. The findings suggest that statins could play a crucial role in managing not only cardiovascular diseases but also a range of inflammatory conditions, warranting further investigation into their full therapeutic potential beyond dyslipidemia. In conclusion, while statins are primarily prescribed for lowering cholesterol, their diverse mechanisms of action highlight their value in preventing and treating inflammatory conditions. This paper emphasizes the need for continued research to fully understand the implications of statins in various clinical settings, particularly in the context of chronic inflammatory diseases and neurodegenerative disorders.

References:

References:
1. Milani E, Saeidi Mehrvarz S, Gholizadeh H. Floristic, life form and chorological studies of the Abshar protected area, Shirgah, Mazandaran Province, north of Iran. Casp. J. Environ. Sci. [Internet] 2017;15:165–80. Available from: https://cjes.guilan.ac.ir/article_2373.html
2. Sashindran Nair K. Alteration in the primary metabolites in three different tissues of silkworm, Bombyx mori L. under the influence of a Juvenoid, R394. Casp. J. Environ. Sci. [Internet] 2007;5:27–33. Available from: https://cjes.guilan.ac.ir/article_981.html
3. Roitman R, Schatton W, Ilyich Maevsky E. Evaluating the environmental and therapeutic impacts of dietary supplement (Case study: The supplement Oyox for prevention of environment damages, treatment and disorders in the hepatobilliary system). Casp. J. Environ. Sci. [Internet] 2021;19:495–502. Available from: https://cjes.guilan.ac.ir/article_4935.html
4. Shojaeian A, Mehri-Ghahfarrokhi A, Banitalebi-Dehkordi M. Monophosphoryl Lipid A and Retinoic Acid Combinations Increased Germ Cell Differentiation Markers Expression in Human Umbilical Cord-derived Mesenchymal Stromal Cells in an In vitro Ovine Acellular Testis Scaffold. Int. J. Mol. Cell. Med. [Internet] 2020;9. Available from: http://ijmcmed.org/article-1-1379-en.html
5. Aghabozorg Afjeh SS, Ghaderian SMH, Mirfakhraie R, Piryaei M, Zaim Kohan H. Association Study of rs3184504 C>T Polymorphism in Patients With Coronary Artery Disease. Int. J. Mol. Cell. Med. [Internet] 2014;3. Available from: http://ijmcmed.org/article-1-145-en.html
6. Shojaee M, Golpasha MF, Maliji G, Bijani A, Mir SMA, Kani SNM. C-reactive protein levels in patients with periodontal disease and normal subjects. Int. J. Mol. Cell. Med. 2013;2:151.
7. Bewicz-Binkowska D, Zgórzyńska E, Dziedzic B, Walczewska A. Docosahexaenoic Acid (DHA) Inhibits FADS2 Expression in Astrocytes but Increases Survival of Neurons Co-cultured with DHA-enriched Astrocytes. Int. J. Mol. Cell. Med. [Internet] 2019;8. Available from: http://ijmcmed.org/article-1-1148-en.html
8. Chandel NS. Lipid metabolism. Cold Spring Harb. Perspect. Biol. 2021;13:a040576.
9. Fu Y, Zou T, Shen X, Nelson PJ, Li J, Wu C, et al. Lipid metabolism in cancer progression and therapeutic strategies. MedComm 2021;2:27–59.
10. Cheng H, Wang M, Su J, Li Y, Long J, Chu J, et al. Lipid Metabolism and Cancer. Life [Internet] 2022;12. Available from: https://www.mdpi.com/2075-1729/12/6/784
11. McKee CA, Lananna B V, Musiek ES. Circadian regulation of astrocyte function: implications for Alzheimer’s disease. Cell. Mol. Life Sci. 2020;77:1049–58.
12. Imierska M, Kurianiuk A, Błachnio-Zabielska A. The influence of physical activity on the bioactive lipids metabolism in obesity-induced muscle insulin resistance. Biomolecules 2020;10:1665.
13. Cao Y, Zhao LW, Chen ZX, Li SH. New insights in lipid metabolism: Potential therapeutic targets for the treatment of Alzheimer’s disease. Front. Neurosci. 2024;18:1430465.
14. A Comparative Study on Body Shape of the Genus Alburnus (Rafinesque, 1820) in Iran, Using Geometric Morphometric Analysis. Casp. J. Environ. Sci. [Internet] 2013;11:205–15. Available from: https://cjes.guilan.ac.ir/article_1126.html
15. Pashaee M, Shiravi A, Hojati V. The effect of hydroalcoholic extract of Berberis vulgaris on wound healing of diabetic wistar rats. 2016;
16. Sizar O, Khare S, Patel P, Talati R. Statin medications. In: StatPearls [Internet]. StatPearls Publishing; 2024.
17. Mira E, Mañes S. Immunomodulatory and anti-inflammatory activities of statins. Endocrine, Metab. Immune Disord. Targets (Formerly Curr. Drug Targets-Immune, Endocr. Metab. Disord. 2009;9:237–47.
18. Medrano Sampayo LE, Mengual Guevara D. Novel effects of statins on cancer via autophagy. 2023;
19. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 2006;6:358–70.
20. Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, et al. Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J. Biol. Chem. 2008;283:25150–63.
21. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. 2008;14:37–44.
22. Razavi AC, Mehta A, Sperling LS. Statin therapy for the primary prevention of cardiovascular disease: Pros. Atherosclerosis 2022;356:41–5.
23. Bucci T, Menichelli D, Palumbo IM, Pastori D, Ames PRJ, Lip GYH, et al. Statins as an Adjunctive Antithrombotic Agent in Thrombotic Antiphospholipid Syndrome: Mechanisms and Clinical Implications. Cells [Internet] 2025;14. Available from: https://www.mdpi.com/2073-4409/14/5/353
24. de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein (a) levels: a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 2022;29:779–92.
25. Correale M, Abruzzese S, A Greco C, Di Biase M, D Brunetti N. Pleiotropic effects of statin in therapy in heart failure: a review. Curr. Vasc. Pharmacol. 2014;12:873–84.
26. Zivkovic S, Maric G, Cvetinovic N, Lepojevic-Stefanovic D, Bozic Cvijan B. Anti-inflammatory effects of lipid-lowering drugs and supplements—A narrative review. Nutrients 2023;15:1517.
27. Koushki K, Shahbaz SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Taba MY, et al. Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways. Clin. Rev. Allergy Immunol. 2021;60:175–99.
28. Şaman E, Cebova M, Barta A, Koneracka M, Zavisova V, Eckstein-Andicsova A, et al. Combined therapy with simvastatin-and coenzyme-q10-loaded nanoparticles upregulates the Akt-eNOS pathway in experimental metabolic syndrome. Int. J. Mol. Sci. 2022;24:276.
29. Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T, et al. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. J. Clin. Med. [Internet] 2019;8. Available from: https://www.mdpi.com/2077-0383/8/12/2051
30. Pickett JR, Wu Y, Zacchi LF, Ta HT. Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1-directed novel therapeutics. Cardiovasc. Res. 2023;119:2278–93.
31. Scioli MG, Storti G, D’Amico F, Rodríguez Guzmán R, Centofanti F, Doldo E, et al. Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets. J. Clin. Med. 2020;9.
32. Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007;28:88–98.
33. Nauryzbaevish AS, Tatarinova G, Berikzhan O, Kunakbayev4 A, Tashenova G, Kapalbaevna AG, et al. Modulation of insulin secretion and lipid profiles through glutamate dehydrogenase activators in diabetic rabbits. Casp. J. Environ. Sci. [Internet] 2023;21:1229–37. Available from: https://cjes.guilan.ac.ir/article_7415.html
34. Satny M, Hubacek JA, Vrablik M. Statins and inflammation. Curr. Atheroscler. Rep. 2021;23:1–8.
35. Gendaszewska-Darmach E, Garstka MA, Błażewska KM. Targeting small GTPases and their prenylation in diabetes mellitus. J. Med. Chem. 2021;64:9677–710.
36. Gholamalizadeh H, Ensan B, Sukhorukov VN, Sahebkar A. Targeting the CCL2–CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases. J. Pharm. Pharmacol. 2024;76:138–53.
37. Libby P. Targeting inflammatory pathways in cardiovascular disease: the inflammasome, interleukin-1, interleukin-6 and beyond. Cells 2021;10:951.
38. Monaco C, McNamara CA, Slütter B, Foks AC, Bekiranov S, Mulder WJM, et al. Immunotherapy for atherosclerosis. Physiol. Rev. 2025;
39. Markovic-Plese S, Singh AK, Singh I. Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol. 2008;3:153.
40. Bedeković D, Bošnjak I, Šarić S, Kirner D, Novak S. Role of Inflammatory Cytokines in Rheumatoid Arthritis and Development of Atherosclerosis: A Review. Medicina (Kaunas). 2023;59.
41. Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmun. Rev. 2015;15.
42. Zinellu A, Mangoni AA. A Systematic Review and Meta-Analysis of the Effect of Statins on Glutathione Peroxidase, Superoxide Dismutase, and Catalase. Antioxidants (Basel, Switzerland) 2021;10.
43. Ray S. Role of statins in the management of dyslipidaemia. Indian Heart J. 2024;76 Suppl 1:S33–7.
44. Johri N, Varshney S, Gandha S, Maurya A, Mittal P, Jangra S, et al. Association of cardiovascular risks in rheumatoid arthritis patients: Management, treatment and future perspectives. Heal. Sci. Rev. [Internet] 2023;8:100108. Available from: https://www.sciencedirect.com/science/article/pii/S277263202300034X
45. Sheng X, Murphy MJ, Macdonald TM, Wei L. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J. Rheumatol. 2012;39:32–40.
46. Soulaidopoulos S, Nikiphorou E, Dimitroulas T, Kitas GD. The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis. Front. Med. 2018;5:24.
47. Semalulu T, Tago A, Zhao K, Tselios K. Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician. ImmunoTargets Ther. 2023;12:175–86.
48. Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J. Cardiovasc. Pharmacol. 2013;62:255–62.
49. Atzeni F, Rodríguez-Pintó I, Cervera R. Cardiovascular disease risk in systemic lupus erythematous: Certainties and controversies. Autoimmun. Rev. [Internet] 2024;23:103646. Available from: https://www.sciencedirect.com/science/article/pii/S156899722400137X
50. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. Jama 2021;325:765–79.
51. von Haehling S, Anker SD, Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail. Rev. 2003;8:99–106.
52. Bhat A, Dalvi H, Jain H, Rangaraj N, Singh SB, Srivastava S. Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal. Curr. Res. Pharmacol. Drug Discov. [Internet] 2021;2:100012. Available from: https://www.sciencedirect.com/science/article/pii/S2590257120300146
53. Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer’s and age-related neurodegenerative diseases. Alzheimer’s Dement. (New York, N. Y.) 2020;6:e12108.
54. Di Sarno A, Romano F, Arianna R, Serpico D, Lavorgna M, Savastano S, et al. Lipid Metabolism and Statin Therapy in Neurodegenerative Diseases: An Endocrine View. Metabolites [Internet] 2025;15. Available from: https://www.mdpi.com/2218-1989/15/4/282
55. Liu C, Chen H, Hu B, Shi J, Chen Y, Huang K. New insights into the therapeutic potentials of statins in cancer. Front. Pharmacol. 2023;14:1188926.